Lexaria Bioscience Corp.
LEXX · NASDAQ
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | 0.06 | -0.07 | 0.19 |
| FCF Yield | -10.33% | -87.13% | -28.76% | -14.90% |
| EV / EBITDA | -7.41 | -0.90 | -1.79 | -2.98 |
| Quality | ||||
| ROIC | -73.79% | -229.74% | -85.68% | -43.21% |
| Gross Margin | 98.96% | 86.07% | 71.87% | 75.74% |
| Cash Conversion Ratio | 0.88 | 0.85 | 0.88 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 46.13% | 22.05% | -32.10% | -6.73% |
| Free Cash Flow Growth | 17.33% | -20.76% | -23.14% | -50.88% |
| Safety | ||||
| Net Debt / EBITDA | 1.12 | 0.19 | 0.88 | 1.95 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.87 | 5.91 |
| Cash Conversion Cycle | -27,988.10 | -2,324.81 | 352.25 | 109.97 |